Hepatocellular carcinoma treated with sorafenib: authors' reply

被引：0
|
作者：
Peck-Radosavljevic, M. [1 ]
Pinter, M. [1 ]
Sieghart, W. [1 ]
机构：
[1] Med Univ Vienna, Dept Gastroenterol & Hepatol, Vienna, Austria
来源：
ALIMENTARY PHARMACOLOGY & THERAPEUTICS | 2011年 / 34卷 / 11-12期
关键词：
D O I：
10.1111/j.1365-2036.2011.04889.x
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：1348 / 1349
页数：2
相关论文
共 50 条
  • [31] Sorafenib - In hepatocellular carcinoma
    Simpson, Dene
    Keating, Gillian M.
    DRUGS, 2008, 68 (02) : 251 - 258
  • [32] Subacute Invasive Aspergillosis Associated With Sorafenib Therapy for Hepatocellular Carcinoma Reply
    Chamilos, Georgios
    Lionakis, Michail S.
    Kontoyiannis, Dimitrios P.
    CLINICAL INFECTIOUS DISEASES, 2018, 67 (01) : 157 - 159
  • [33] Commentary: predicting survival in hepatocellular carcinoma patients - authors' reply
    Crooks, C.
    Card, T.
    West, J.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2012, 36 (07) : 681 - 682
  • [34] Editorial: TIPSS in patients with cirrhosis and hepatocellular carcinoma - authors' reply
    Bettinger, D.
    Knueppel, E.
    Euringer, W.
    Spangenberg, H. C.
    Roessle, M.
    Thimme, R.
    Schultheiss, M.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2015, 41 (02) : 231 - 231
  • [35] Factors Contributing to the Overall Survival in Patients with Hepatocellular Carcinoma Treated by Sorafenib
    Tsukui, Yuya
    Mochizuki, Hitoshi
    Hoshino, Yuji
    Kawakami, Satoshi
    Kuno, Toru
    Fukasawa, Yoshimitsu
    Iwamoto, Fumihiko
    Hirose, Sumio
    Yoshida, Takashi
    Hosoda, Kenji
    Suzuki, Youji
    Hosoda, Kazuhiko
    Kojima, Yuichiro
    Hirose, Yuichi
    Shindou, Kuniaki
    Matsuda, Masanori
    Yagawa, Syoji
    Tawara, Akio
    Kobayashi, Masashi
    Konishi, Toshiyuki
    Yamazaki, Takahisa
    Takahashi, Seiichiro
    Fujii, Hideki
    Enomoto, Nobuyuki
    Omata, Masao
    HEPATO-GASTROENTEROLOGY, 2012, 59 (120) : 2536 - 2539
  • [36] Tolerance and outcomes of sorafenib in elderly patients treated for advanced hepatocellular carcinoma
    Williet, Nicolas
    Clavel, Lea
    Bourmaud, Aurelie
    Verot, Celine
    Bouarioua, Nadia
    Roblin, Xavier
    Merle, Philippe
    Phelip, Jean-Marc
    DIGESTIVE AND LIVER DISEASE, 2017, 49 (09) : 1043 - 1049
  • [37] Predictive significance of circulating histones in hepatocellular carcinoma patients treated with sorafenib
    Salani, Francesca
    Latarani, Maryam
    Casadei-Gardini, Andrea
    Gangadharannambiar, Priyadarsini
    Fornaro, Lorenzo
    Vivaldi, Caterina
    Pecora, Irene
    Massa, Valentina
    Marisi, Giorgia
    Canale, Matteo
    Ulivi, Paola
    Scartozzi, Mario
    Eccleston, Mark
    Masi, Gianluca
    Crea, Francesco
    EPIGENOMICS, 2022, 14 (09) : 507 - 517
  • [38] The role of PNI to predict survival in advanced hepatocellular carcinoma treated with Sorafenib
    Caputo, Francesco
    Dadduzio, Vincenzo
    Tovoli, Francesco
    Bertolini, Giulia
    Cabibbo, Giuseppe
    Cerma, Krisida
    Vivaldi, Caterina
    Faloppi, Luca
    Rizzato, Mario Domenico
    Piscaglia, Fabio
    Celsa, Ciro
    Fornaro, Lorenzo
    Marisi, Giorgia
    Conti, Fabio
    Silvestris, Nicola
    Silletta, Marianna
    Lonardi, Sara
    Granito, Alessandro
    Stornello, Caterina
    Massa, Valentina
    Astara, Giorgio
    Delcuratolo, Sabina
    Cascinu, Stefano
    Scartozzi, Mario
    Casadei-Gardini, Andrea
    PLOS ONE, 2020, 15 (05):
  • [39] Overall Survival in Patients with Hepatocellular Carcinoma Treated with Sorafenib: A Polish Experience
    Stras, Wojciech
    Gotlib, Joanna
    Malkowski, Piotr
    Wasiak, Dariusz
    Sliwczynski, Andrzej
    Panczyk, Mariusz
    Tronina, Olga
    Brzozowska, Melania
    MEDICAL SCIENCE MONITOR, 2021, 27
  • [40] Molecular determinants of outcome in sorafenib-treated patients with hepatocellular carcinoma
    Personeni, Nicola
    Rimassa, Lorenza
    Pressiani, Tiziana
    Destro, Annarita
    Ligorio, Claudia
    Tronconi, Maria Chiara
    Bozzarelli, Silvia
    Carnaghi, Carlo
    Di Tommaso, Luca
    Giordano, Laura
    Roncalli, Massimo
    Santoro, Armando
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2013, 139 (07) : 1179 - 1187
12345